{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:38:42Z","timestamp":1767145122150,"version":"build-2238731810"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.anndiagpath.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:47:44Z","timestamp":1560430064000},"page":"124-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center"],"prefix":"10.1016","volume":"41","author":[{"given":"Patrick","family":"McIntire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reema","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irem","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva M.","family":"Wojcik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan E.","family":"Pambuccian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcliz A.","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0005","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.6004\/jnccn.2009.0004","article-title":"Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis","volume":"7","author":"Nese","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0015","unstructured":"Society AC. American Cancer Society: Cancer facts and figures 2018. [accessed February 26th, 2019]."},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0022-5347(17)61913-X","article-title":"The plight of the patient with carcinoma in situ of the bladder","volume":"103","author":"Utz","year":"1970","journal-title":"J Urol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0025","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U","article-title":"Survival of patients with carcinoma in situ of the urinary bladder","volume":"85","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.eururo.2006.08.037","article-title":"Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-001-0577-6","article-title":"Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation","volume":"440","author":"Lopez-Beltran","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0040","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00345-006-0114-y","article-title":"Bladder-sparing approaches to invasive disease","volume":"24","author":"Efstathiou","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0055","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/1354750X.2018.1428360","article-title":"Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm","volume":"23","author":"Sanguedolce","year":"2018","journal-title":"Biomarkers"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0065","first-page":"75","article-title":"Diagnosis of intraurothelial neoplasia. Interobserver variation and the value of individual histopathologic attributes","volume":"33","author":"Isfoss","year":"2011","journal-title":"Anal Quant Cytol Histol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PAI.0000000000000401","article-title":"Flat urothelial lesions with atypia: Interobserver concordance and added value of Immunohistochemical profiling","volume":"26","author":"Lawless","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","article-title":"Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia","volume":"16","author":"Mallofre","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","article-title":"Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens","volume":"25","author":"McKenney","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0085","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0090","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00129039-200212000-00007","article-title":"p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder","volume":"10","author":"Sun","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0095","first-page":"46","article-title":"A useful panel in proliferative urothelial lesions: an analysis of cytokeratin 20, p53, CD44 and Ki-67 antigens","volume":"99","author":"Russo","year":"2007","journal-title":"Pathologica"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0100","first-page":"400","article-title":"Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: analysis of CK20, CD44, P53 and Ki67","volume":"30","author":"Asgari","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1746-1596-4-35","article-title":"Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies","volume":"4","author":"Yildiz","year":"2009","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"CK20 and p53 immunohistochemical staining patterns in urinary bladder specimens with equivocal atypia","volume":"142","author":"Arias-Stella","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","article-title":"The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5\/6, P53, Cd138, and Her2\/Neu","volume":"18","author":"Jung","year":"2014","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0120","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and alpha-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2019.06.002_bb0125","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Members of the IIiDUPG. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am J Surg Pathol"}],"updated-by":[{"DOI":"10.1016\/j.anndiagpath.2020.151513","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000}}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109291341930214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109291341930214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T14:54:56Z","timestamp":1663685696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109291341930214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":25,"alternative-id":["S109291341930214X"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.06.002","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}